Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants

Rhea-AI Filing Summary

Atea Pharmaceuticals director Jerome M. Adams reported equity compensation and a routine derivative exercise. On June 18, 2026, he exercised 29,600 shares of previously granted restricted stock units into Common Stock, leaving him with 92,350 Common shares held directly.

On the same date, he received a new grant of 37,700 stock options with a $4.36 exercise price, expiring on June 17, 2036, which vest in twelve equal monthly installments after June 18, 2026. He was also granted 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.

Insights

Equity compensation analyst

Routine director equity awards and RSU exercise with no share sales.

Director Jerome M. Adams exercised 29,600 restricted stock units into Common Stock for no cash consideration and now directly holds 92,350 shares. This converts previously awarded equity into outright share ownership, without any reported market sales.

He also received a new grant of 37,700 stock options at a $4.36 exercise price, vesting monthly through June 18, 2027, plus 26,700 restricted stock units that vest by the next annual meeting or by June 18, 2027. These are standard director compensation structures, and the filing does not show open‑market buying or selling, so the overall signal is routine and neutral.

Insider Trade Summary

29,600 shares exercised/converted

Mixed 4 txns

Insider Adams Jerome M.

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	29,600	$0.00	--
Grant/Award	Restricted Stock Units	26,700	$0.00	--
Grant/Award	Stock Option (Right to Buy)	37,700	$0.00	--
Exercise	Common Stock	29,600	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Stock Option (Right to Buy) — 37,700 shares (Direct, null); Common Stock — 92,350 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested in full on June 18, 2026. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

RSUs exercised into Common Stock: 29,600 shares Common shares held after transactions: 92,350 shares New stock options granted: 37,700 options +4 more

7 metrics

RSUs exercised into Common Stock 29,600 shares Converted to Common Stock on June 18, 2026

Common shares held after transactions 92,350 shares Direct ownership after June 18, 2026 exercise

New stock options granted 37,700 options Grant on June 18, 2026

Stock option exercise price $4.36 per share For 37,700 options expiring June 17, 2036

New RSUs granted 26,700 units Grant on June 18, 2026

Option vesting period 12 monthly installments Following June 18, 2026, fully vested by June 18, 2027

RSU vesting deadline June 18, 2027 Or earlier at next annual stockholder meeting after June 18, 2026

Key Terms

Restricted Stock Units, Stock Option (Right to Buy), vested in full, annual meeting of the Issuer's stockholders, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of 4.3600"

vested in full financial

"The RSUs vested in full on June 18, 2026."

annual meeting of the Issuer's stockholders financial

"on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders"

substantially equal monthly installments financial

"The option vests and becomes exercisable in twelve (12) substantially equal monthly installments"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:00 PM Accepted by SEC EDGAR 06/23/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adams Jerome M.

(Last) (First) (Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		M		29,600	A	$0(1)	92,350	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/18/2026		M			29,600	(2)	(2)	Common Stock	29,600	$0	0	D
Restricted Stock Units	(1)	06/18/2026		A		26,700		(3)	(3)	Common Stock	26,700	$0	26,700	D
Stock Option (Right to Buy)	$4.36	06/18/2026		A		37,700		(4)	06/17/2036	Common Stock	37,700	$0	37,700	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. The RSUs vested in full on June 18, 2026.

3. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

4. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Jerome M. Adams	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Atea Pharmaceuticals (AVIR) director Jerome M. Adams report in this Form 4?

He reported exercising 29,600 restricted stock units into Common Stock and receiving new equity awards. After these transactions, he directly holds 92,350 Common shares, plus new stock options and RSUs subject to future vesting conditions.

Did Jerome M. Adams buy or sell Atea Pharmaceuticals (AVIR) shares on the open market?

No open-market purchases or sales were reported. The Form 4 shows a derivative exercise of 29,600 restricted stock units into Common Stock and grants of stock options and RSUs, all as compensation-related equity movements rather than market trades.

What new stock options did Jerome M. Adams receive from Atea Pharmaceuticals (AVIR)?

He received 37,700 stock options with a $4.36 exercise price, expiring June 17, 2036. These options vest in twelve substantially equal monthly installments following June 18, 2026, becoming fully vested by June 18, 2027, subject to his continued board service.

How many restricted stock units did Jerome M. Adams receive from Atea Pharmaceuticals (AVIR)?

He was granted 26,700 restricted stock units, each representing one share of Common Stock. These RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, conditioned on continued service.

How many Atea Pharmaceuticals (AVIR) shares does Jerome M. Adams own after these transactions?

After exercising 29,600 restricted stock units, he directly holds 92,350 shares of Atea Pharmaceuticals Common Stock. This figure reflects his direct ownership position following the June 18, 2026 equity transactions reported in the Form 4.

Did any of Jerome M. Adams’s restricted stock units in Atea Pharmaceuticals (AVIR) fully vest?

Yes. One RSU grant vested in full on June 18, 2026, and 29,600 vested units were converted into Common Stock. A separate 26,700-unit RSU grant will vest later, subject to timing tied to the next annual meeting or June 18, 2027.